Process for concentration of antibodies and therapeutic products thereof
View Patent ↗This present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process of preparing highly concentrated antibody compositions. and highly concentrated antibody products.
1. A process for preparing a concentrated anti-IgE rhuMAb E25 antibody composition, comprising:
a) concentrating a first purified antibody preparation by a first ultrafiltering to provide a second antibody preparation comprising a retentate of the first ultrafiltering in a first buffer, wherein the first purified antibody preparation has been purified with ion-exchange chromatography prior to step a);
b) exchanging the first buffer of the second antibody preparation generated in step a) into a second buffer by a diafiltering to provide a diafiltered intermediate antibody preparation comprising a retentate of the diafiltering; and
c) concentrating the diafiltered intermediate antibody preparation generated in step b) by a second ultrafiltering to provide a third antibody preparation comprising a retentate of the second ultrafiltering, wherein the third antibody preparation has an antibody concentration from greater than 150 grams per liter to 250 grams per liter;
wherein one or more of the first ultrafiltering, the second ultrafiltering, and the diafiltering are carried out at a temperature of 35° C. to 50° C.,
wherein the first ultrafiltering and the second ultrafiltering are accomplished with an ultra-filter membrane having a nominal pore size of about 5 to about 50 kilo Daltons, and
wherein the anti-IgE rhuMAb E25 antibody is as described in U.S. Pat. No. 6,172,213.
2. The process of claim 1 , wherein the ion-exchange chromatography comprises anion-exchange chromatography.
3. The process of claim 1 , wherein one or more of the first ultrafiltering, the second ultrafiltering, and the diafiltering are carried out at a temperature of 45° C. plus or minus 5° C.
4. The process of claim 1 , wherein one or more of the first ultrafiltering, the second ultrafiltering, and the diafiltering are accomplished at 45° C.
5. The process of claim 1 , wherein the first purified antibody preparation has an antibody concentration of from about 0.1 to about 10 grams per liter, and the second antibody preparation has an antibody concentration of from about 10 to about 50 grams per liter.
6. The process of claim 1 , wherein the first purified antibody preparation has an antibody concentration of from about 1 to about 5 grams per liter and the second antibody preparation has an antibody concentration of from about 20 to about 40 grams per liter.
7. The process of claim 1 , wherein the third antibody preparation has an antibody concentration of from about 170 to about 200 grams per liter.
8. The process of claim 1 , wherein the process is accomplished in from about 1 to 10 hours.
9. The process of claim 1 , wherein the process is accomplished in from about 2 to 5 hours.
10. The process of claim 1 , wherein the process is accomplished in about 3 hours.
11. The process of claim 1 , wherein the first ultrafiltering and the second ultrafiltering are accomplished with an ultra-filter membrane having a nominal pore size of about 10 to about 30 kilo Daltons.
12. The process of claim 1 , wherein the first ultrafiltering and the second ultrafiltering are accomplished with the same ultra-filter membrane.
13. The process of claim 1 , wherein the first ultrafiltering and the second ultrafiltering are accomplished with a regenerated cellulose composite ultra-filter membrane.
14. The process of claim 1 , wherein the diafiltering accomplishes a buffer exchange at a constant antibody concentration.
15. The process of claim 1 , wherein the diafiltering accomplishes a buffer exchange of from about 5 to about 15 fold volumes.
16. The process of claim 1 wherein the first buffer comprises a mixture of aqueous sodium chloride and a TRIS buffer, and the second buffer comprises a mixture of aqueous histidine chloride and arginine chloride.
17. The process of claim 1 , wherein the first ultrafiltering, the second ultrafiltering, and the diafiltering are accomplished with tangential flow filtration across the ultra-filter membrane.
18. The process of claim 1 , wherein the yield of the third antibody preparation is greater than 70 weight percent based on the weight of antibodies in the first purified antibody preparation.
19. The process of claim 18 , wherein the yield of the third antibody preparation is from 80 to 100 weight percent based on the weight of antibodies in the first purified antibody preparation.
20. The process of claim 19 , wherein the yield of the third antibody preparation is greater than about 98 weight percent based on the weight of the antibody in the first purified antibody preparation.
21. The process of claim 1 , wherein the first ultrafiltering has a recirculation rate of from about 0.5 L/min/ft 2 to about 5 L/min/ft 2.
22. The process of claim 1 wherein the ultrafiltering and diafiltering are accomplished at a transmembrane pressure of from about 10 to about 50 p.s.i.
23. The process of claim 1 , wherein the first ultrafiltering, the second ultrafiltering, and the diafiltering are accomplished with tangential flow filtration across an ultra-filter membrane.
24. The process of claim 1 , wherein the first ultrafiltering, the second ultrafiltering, and the diafiltering are accomplished with tangential flow filtration across the same ultra-filter membrane.
25. The process of claim 1 , wherein the third antibody preparation is further processed using nanofiltration and/or reverse osmosis.
26. The process of claim 1 , wherein the aggregated contaminants in the third antibody preparation are less than 5 weight percent.
27. The process of claim 1 , wherein the aggregated contaminants in the third antibody preparation are less than 2 weight percent.
28. The process of claim 1 , further comprising diluting the third antibody preparation to produce a final formulation with an antibody concentration of about 150 g/L antibody, wherein the final formulation is substantially free from aggregates.
29. The process of claim 28 , wherein the final formulation has an antibody concentration of about 150 g/L antibody in 0.02 M histidine, 0.2 M arginine-HCl, and 0.04% polysorbate 20 , pH 6.